Generation of medical assisting tools using recent artificial intelligence advances is beneficial for the medical workers in the global fight against COVID-19 outbreak. In this article we introduce ai-corona, a radiologist-assistant deep learning framework for COVID-19 infection diagnosis using chest CT scans. Our framework incorporates an Efficient NetB3-based feature extractor. We employed three independent dataset in this work named: CC-CCII, MDH, and MosMedData; all includes 7184 scans from 5693 subjects which contained pneumonia, common pneumonia (CP), non-pneumonia, normal and COVID-19 classes. We evaluated ai-corona on test sets from the CC-CCII set and MDH cohort and the entirety of the MosMedData cohort, for which it gained AUC score of 0.997, 0.989, and 0.954, respectively. We further compared our framework9s performance with other deep learning models developed on our employed data sets, as well as RT-PCR. Our results show that ai-corona outperforms all. Lastly, our framework9s diagnosis capabilities was evaluated as assistant to several experts. We demonstrated an increase in both speed and accuracy of expert diagnosis when incorporating ai-corona9s assistance.
The double dose regimen for mRNA vaccines against SARS-CoV-2 presents both a hope and a challenge for global efforts to curb the COVID-19 pandemic. With supply chain logistics impacting the rollout of population-scale vaccination programs, increasing attention has turned to the potential efficacy of single versus double dose vaccine administration for select individuals. To this end, we examined response to Pfizer-BioNTech mRNA vaccine in a large cohort of healthcare workers including those with versus without prior COVID-19 infection. For all participants, we quantified circulating levels of SARS-CoV-2 anti-spike (S) protein IgG at baseline prior to vaccine, after vaccine dose 1, and after vaccine dose 2. We observed that the anti-S IgG antibody response following a single vaccine dose in persons who had recovered from confirmed prior COVID-19 infection was similar to the antibody response following two doses of vaccine in persons without prior infection (P>0.57). Patterns were similar for the post-vaccine symptoms experienced by infection recovered persons following their first dose compared to the symptoms experienced by infection naive persons following their second dose (P=0.66). These results support the premise that a single dose of mRNA vaccine could provoke in COVID-19 recovered individuals a level of immunity that is comparable to that seen in infection naive persons following a double dose regimen. Additional studies are needed to validate our findings, which could allow for public health programs to expand the reach of population wide vaccination efforts.
Objectives: Describe a new England-wide electronic health record (EHR) resource enabling whole population research on Covid-19 and cardiovascular disease whilst ensuring data security and privacy and maintaining public trust. Design: Cohort comprising linked person-level records from national healthcare settings for the English population accessible within the new NHS Digital Trusted Research Environment. Setting: EHRs from primary care, hospital episodes, death registry, Covid-19 laboratory test results and community dispensing data, with further enrichment planned from specialist intensive care, cardiovascular and Covid-19 vaccination data. Participants: 54.4 million people alive on 1st January 2020 and registered with an NHS general practitioner in England. Main measures of interest: Confirmed and suspected Covid-19 diagnoses, exemplar cardiovascular conditions (incident stroke or transient ischaemic attack (TIA) and incident myocardial infarction (MI)) and all-cause mortality between 1st January and 31st October 2020. Results: The linked cohort includes over 96% of the English population. By combining person-level data across national healthcare settings, data on age, sex and ethnicity are complete for over 95% of the population. Among 53.2M people with no prior diagnosis of stroke/TIA, 98,721 had an incident stroke/TIA, of which 30% were recorded only in primary care and 4% only in death registry records. Among 53.1M people with no prior history of MI, 62,966 had an incident MI, of which 8% were recorded only in primary care and 12% only in death records. A total of 959,067 people had a confirmed or suspected Covid-19 diagnosis (714,162 in primary care data, 126,349 in hospital admission records, 776,503 in Covid-19 laboratory test data and 48,433 participants in death registry records). While 58% of these were recorded in both primary care and Covid-19 laboratory test data, 15% and 18% respectively were recorded in only one. Conclusions: This population-wide resource demonstrates the importance of linking person-level data across health settings to maximize completeness of key characteristics and to ascertain cardiovascular events and Covid-19 diagnoses. Although established initially to support research on Covid-19 and cardiovascular disease to benefit clinical care and public health and to inform health care policy, it can broaden further to enable a very wide range of research.
Background Austria, and particularly its westernmost federal state Vorarlberg, developed an extremely high COVID-19 incidence rate in November 2020. Health care workers (HCW) may be at higher risk of contracting the disease within the working environment and therefore the seroprevalence in this population is of particular interest. Here, we analyzed SARS-CoV-2-specific antibody response in Vorarlberg HCW in a prospective cohort study. Methods A total of 395 HCW have been tested at three different time points for the prevalence of anti-SARS-CoV-2 IgG antibodies specific for NP and RBD. Enrollment started in June 2020 (t1), two months after the end of the first wave. Re-testing took place between October to November at the beginning of the second wave (t2), and again at the end of the second wave in January 2021 (t3). Results At t1, 3% of HCW showed a strong IgG-specific responses to either NP or RBD. At t2, the rate increased to 4%, and after the second wave in January 2021, 14% had a strong response, which was assessed to be stable for up to ten months. The amount of HCW with anti-SARS-CoV-2 IgG antibodies was 38% higher than the number of infections found by RT-PCR. Conclusion We found low numbers of SARS-CoV-2-seropositive HCW in a hotspot setting after the first wave but a very high increase during the second massive wave. Though the seroprevalence in HCW was comparable to the general population. Our findings offer support for the routine application of serological testing in management of the ongoing COVID-19 pandemic.
Importance: A significant proportion of COVID-19 transmission occurs silently during the pre-symptomatic and asymptomatic stages of infection. Children, while being important drivers of silent transmission, are not included in the current COVID-19 vaccination campaigns. Objective: To investigate the benefits of identifying silent infections among children as a proxy for their vaccination. Design: This study used an age-structured disease transmission model, parameterized with census data and estimates from published literature, to simulate the synergistic effect of interventions in reducing attack rates over the course of one year. Setting: A synthetic population representative of the United States (US) demographics. Participants: Six age groups of 0-4, 5-10, 11-18, 19-49, 50-64, 65+ years based on US census data. Interventions: In addition to the isolation of symptomatic cases within 24 hours of symptom onset, vaccination of adults was implemented to reach a 40%-60% coverage over the course of one year with an efficacy of 95% against symptomatic and severe COVID-19. Main Outcomes and Measures: The combinations of proportion and speed for detecting silent infections among children which would suppress future attack rates below 5%. Results: In the base-case scenarios with an effective reproduction number Re = 1.2, a targeted approach that identifies 11% and 14% of silent infections among children within 2 or 3 days post-infection, respectively, would bring attack rates under 5% with 40% vaccination coverage of adults. If silent infections among children remained undetected, achieving the same attack rates would require an unrealistically high vaccination coverage (at least 81%) of this age group, in addition to 40% vaccination coverage of adults. The effect of identifying silent infections was robust in sensitivity analyses with respect to vaccine efficacy against infection and reduced susceptibility of children to infection. Conclusions and Relevance: In this simulation modeling study of a synthetic US population, in the absence of vaccine availability for children, a targeted approach to rapidly identify silent COVID-19 infections in this age group was estimated to significantly mitigate disease burden. Without measures to interrupt transmission chains from silent infections, vaccination of adults is unlikely to contain the outbreaks in the near term.
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19 - Condition: Covid19
Interventions: Biological: COVI-AMG; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
COVID-19 Antithrombotic Rivaroxaban Evaluation - Condition: COVID-19
Intervention: Drug: Rivaroxaban 10 mg
Sponsors: Hospital Alemão Oswaldo Cruz; Bayer; Hospital Israelita Albert Einstein; Hospital do Coracao; Hospital Sirio-Libanes; Hospital Moinhos de Vento; Brazilian Research In Intensive Care Network; Brazilian Clinical Research Institute
Recruiting
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection - Condition: Covid19
Interventions: Drug: FB2001; Drug: FB2001 Placebo
Sponsor: Frontier Biotechnologies Inc.
Not yet recruiting
A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 - Condition: COVID-19
Interventions: Drug: BRII-196 and BRII-198; Drug: Placebo
Sponsor: Brii Biosciences, Inc.
Not yet recruiting
Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19 - Condition: Covid19
Intervention: Other: prone position
Sponsor: Southeast University, China
Not yet recruiting
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients - Condition: Covid19
Intervention: Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
Sponsors: Makerere University; Ministry of Health, Uganda; Mbarara University of Science and Technology; Joint Clinical Research Center
Not yet recruiting
Protecting Native Families From COVID-19 - Condition: COVID-19
Interventions: Behavioral: Motivational Interviewing; Behavioral: COVID-19 Symptom Monitoring System; Behavioral: Motivational Interviewing and COVID-19 Symptom Monitoring System; Other: Supportive Services
Sponsor: Johns Hopkins Bloomberg School of Public Health
Not yet recruiting
Honey and Nigella Sativa in COVID-19 Prophylaxis - Condition: Covid19
Interventions: Drug: Honey; Drug: Nigella sativa seed; Other: Placebo
Sponsor: Sohaib Ashraf
Recruiting
Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras - Condition: COVID-19
Intervention: Biological: Thymic peptides
Sponsors: Universidad Católica de Honduras; Pontificia Universidad Catolica de Chile
Recruiting
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a) - Condition: Covid19
Interventions: Biological: VBI-2902a; Biological: Placebo
Sponsor: VBI Vaccines Inc.
Not yet recruiting
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) - Condition: Covid19
Interventions: Biological: AZD1222; Biological: rAd26-S
Sponsors: R-Pharm; AstraZeneca
Not yet recruiting
Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients - Condition: Covid19
Interventions: Dietary Supplement: MAF capsules 148 mg; Dietary Supplement: M capsules 148 mg; Other: Standard of care
Sponsor: Saisei Pharma
Active, not recruiting
Impact of Colchicine and Low-dose Naltrexone on COVID-19 - Condition: Covid19
Interventions: Drug: Colchicine 0.6 mg; Drug: Naltrexone
Sponsors: HealthPartners Institute; Park Nicollet Foundation
Enrolling by invitation
THE EFFECT OF BREATHING EXERCISE AFTER COVID-19 PNEUMONIA: A Randomised Controlled Study - Condition: Covid19
Interventions: Other: Breathing exercise with the phone application; Other: Breathing exercise
Sponsor: Tokat Gaziosmanpasa University
Not yet recruiting
The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing - Condition: Covid19
Intervention: Diagnostic Test: Spartan COVID-19 Platform
Sponsor: Ottawa Heart Institute Research Corporation
Not yet recruiting
In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Understanding of the RNA virus and its interactions with host proteins could improve therapeutic interventions for COVID-19. By using icSHAPE, we determined the structural landscape of SARS-CoV-2 RNA in infected human cells and from refolded RNAs, as well as the regulatory untranslated regions of SARS-CoV-2 and six other coronaviruses. We validated several…
Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication - Cytoplasmic stress granules (SGs) are generally triggered by stress-induced translation arrest for storing mRNAs. Recently, it has been shown that SGs exert anti-viral functions due to their involvement in protein synthesis shut off and recruitment of innate immune signaling intermediates. The largest RNA viruses, coronaviruses, impose great threat to public safety and animal health; however, the significance of SGs in coronavirus infection is largely unknown. Infectious Bronchitis Virus (IBV)…
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans - Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral responses were detected within 3 weeks of onset of illness in all patients and the serological titre was elicited soon after or concomitantly with peripheral plasmablast response. An average of 13.7% and 13.0% of plasmablast-derived MAbs were reactive with virus spike glycoprotein or nucleocapsid,…
Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein - No abstract
Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable? - No abstract
Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: A descriptive study of fibrinolysis - BACKGROUND: Accumulating evidence indicates towards an association between SARS-CoV-2 infection and procoagulatory state in blood. Thromboelastographic investigations are useful point-of-care devices to assess coagulation and fibrinolysis.
Plant-Derived Food Grade Substances (PDFGS) Active Against Respiratory Viruses: A Systematic Review of Non-clinical Studies - Human diet comprises several classes of phytochemicals some of which are potentially active against human pathogenic viruses. This study examined available evidence that identifies existing food plants or constituents of edible foods that have been reported to inhibit viral pathogenesis of the human respiratory tract. SCOPUS and PUBMED databases were searched with keywords designed to retrieve articles that investigated the effect of plant-derived food grade substances (PDFGS) on the activities…
Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study - Corticosteroid is commonly used to reduce damage from inflammatory reactions in coronavirus disease 2019 (COVID-19). We aim to determine the outcomes of corticosteroid use in critically ill COVID-19 patients. Ninety six critically ill patients, hospitalized in 14 hospitals outside Wuhan from January 16 to March 30, 2020 were enrolled in this study. Among 96 critical patients, 68 were treated with corticosteroid (CS group), while 28 were not treated with corticosteroids (non-CS group)….
How Family’s Support of Perseverance in Creative Efforts Influences the Originality of Children’s Drawing During the Period of COVID-19 Pandemic? - This study points out that families’ support of perseverance in creative efforts will increase children’s originality of creative drawing through children’s persistence in information searching. Data analysis based on 134 Chinese young children’s creative drawings and survey supports the above hypothesis. Moreover, children’s exposure to COVID-19 pandemic positively moderates the relationship between supporting perseverance and children’s search persistence, such that high exposure to COVID-19…
Impact of the COVID-19 lockdown on roadside traffic-related air pollution in Shanghai, China - The outbreak of COVID-19 has significantly inhibited global economic growth and impacted the environment. Some evidence suggests that lockdown strategies have significantly reduced traffic-related air pollution (TRAP) in regions across the world. However, the impact of COVID-19 on TRAP on roadside is still not clearly understood. In this study, we assessed the influence of the COVID-19 lockdown on the levels of traffic-related air pollutants in Shanghai. The pollution data from two types of…
Neutrophil Extracellular Traps in Coronavirus Disease-19-Associated Ischemic Stroke: A Novel Avenue in Neuroscience - Ischemic stroke is one of the catastrophic neurological events that are being increasingly recognized among Coronavirus Disease (COVID)-19 patients. The recent studies have revealed about a possible connection among COVID-19, ischemic stroke, and excessive Neutrophil Extracellular Traps (NETs) formation. This paper establishes an overview of coronaviruses and NETs, NETs in pathogenesis of COVID-19 induced-ischemic stroke, and future directions using related recent literatures. NETs are normally…
Antiviral Bafilomycins from a Feces-Inhabiting Streptomyces sp - A new bafilomycin derivative (1) and another seven known bafilomycins (2-8) were isolated from feces-derived Streptomyces sp. HTL16. The structure of 1 was elucidated by 1D and 2D NMR spectroscopic analysis. Biological testing demonstrated that these bafilomycins exhibited potent antiviral activities against the influenza A and SARS-CoV-2 viruses, with IC(50) values in the nanomolar range, by inhibiting the activity of endosomal ATP-driven proton pumps.
Ca(2+)-dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide - Cell penetration after recognition of the SARS-CoV-2 virus by the ACE2 receptor, and the fusion of its viral envelope membrane with cellular membranes, are the early steps of infectivity. A region of the Spike protein (S) of the virus, identified as the “fusion peptide” (FP), is liberated at its N-terminal site by a specific cleavage occurring in concert with the interaction of the receptor binding domain of the Spike. Studies have shown that penetration is enhanced by the required binding of…
Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup - No abstract
A pilot double-blind safety and feasibility randomised controlled trial of high-dose intravenous zinc in hospitalised COVID-19 patients - CONCLUSION: Hospitalised COVID-19 patients demonstrated zinc deficiency. This can be corrected with HDIVZn. Such treatment appears safe, feasible and only associated with minimal peripheral infusion site irritation. This pilot study justifies further investigation of this treatment in COVID-19 patients. This article is protected by copyright. All rights reserved.
Sars-CoV-2 vaccine antigens - - link
SARS-COV-2 BINDING PROTEINS - - link
Compositions and methods for detecting SARS-CoV-2 spike protein - - link
一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用 - 本发明涉及医药技术领域,公开了一种3‑羟基丁酰化修饰蛋白质药物(例如抗体)及其制备方法和应用,特别是一种3‑羟基丁酰化修饰抗体及其制备方法和应用。发明人经过大量实验发现,3‑羟基丁酸及其类似物修饰蛋白质药物(例如抗体)后,可以显著提高蛋白质药物的热稳定性、对蛋白酶水解的抗性,降低蛋白质药物的等电点,并显著延长其在受试者体内的半衰期,进而提高其药效。修饰后所得蛋白质药物在科研和临床方面具有广阔的应用前景和较高的商业价值。 - link
新冠病毒重组融合蛋白、其制备方法和应用 - 本发明提供一种新冠病毒重组融合蛋白、其制备方法和应用。本发明通过对新冠病毒S和N重组融合蛋白的基因序列进行设计,选择最优的片段进行整合,再通过人源HEK293细胞系统重组表达融合蛋白,经过纯化后对融合蛋白的分子量、纯度进行检测,最后利用融合蛋白制成新冠病毒抗体胶体金检测试纸条/试剂盒。与单独使用S蛋白或N蛋白制备的胶体金检测试纸条相比,该重组融合蛋白制备的胶体金检测试纸条具有更高的灵敏度和更低的漏检率。此外,本发明提供的新冠病毒重组融合蛋白可广泛应用于不同平台技术的新冠抗体检测试剂盒开发,如胶体金、荧光免疫层析、化学发光和酶联免疫等。 - link
稳定的冠状病毒重组蛋白二聚体及其表达载体 - 本发明公开了稳定的冠状病毒重组蛋白二聚体及其表达载体,冠状病毒重组蛋白,由冠状病毒S蛋白S‑RBD、冠状病毒N蛋白的CTD区N‑CTD和将二者偶联的连接子构成。本发明一些实例的冠状病毒重组蛋白,可以形成并维持稳定的二聚体结构,避免单体S‑RBD降解,有利于提高冠状病毒重组蛋白的免疫原性,有望用于制备检测试剂原料、疫苗、抗体、预防或治疗性药物。本发明一些实例的冠状病毒重组蛋白二聚体,具有很好的免疫原性。在疫苗开发领域具有广阔的应用前景。本发明一些实例的表达载体,易于表达冠状病毒重组蛋白二聚体且表达量高。 - link
SELF-CLEANING AND GERM-KILLING REVOLVING PUBLIC TOILET FOR COVID 19 - - link
一种新冠病毒S1蛋白的灌流生产系统及方法 - 本发明涉及细胞生物学技术领域,提供了一种新冠病毒S1蛋白的灌流生产系统及方法,包括:细胞反应器,用于培养表达S1蛋白的细胞株;灌流系统,包括过滤装置、出液管、回液管和第一循环泵,所述过滤装置的主体内设有孔径为0.1‑0.2μm的中空纤维柱,用于过滤透出液,截留细胞培养液中的S1蛋白;所述出液管的两端分别与所述细胞反应器和所述中空纤维柱的下端相连通;所述回液管的两端分别与所述细胞反应器和所述中空纤维柱的上端相连通;所述第一循环泵设置于所述出液管与所述中空纤维柱相连的管路中。本发明系统投入成本低且S1蛋白产量高。 - link
检测新冠病毒的方法及试剂盒 - 本发明公开了一种检测新冠病毒的方法及试剂盒。其中,该方法包括以下步骤:1)采集样本;2)采用核酸释放剂提取核酸;3)采用LAMP扩增进行检测,其中,核酸释放剂包括:热敏蛋白酶1000U/L~10000U/L、Tris‑HCl 5~50 mmol/L、曲拉通X‑100体积百分比0.05%0.5%和金属离子螯合剂0.10.5mmol/L,其余为无菌水,热敏蛋白酶为≥55℃加热5~10分钟会完全失活的蛋白酶。应用本发明的检测新冠病毒的方法及试剂盒,检测新冠病毒,检测周期短,操作简单方便,检测结果通俗易懂,检测特异性高,检测成本低。 - link
一种新型冠状病毒拉曼光谱数据中心的构建方法 - 本发明公开了一种新型冠状病毒拉曼光谱数据中心的构建方法,该方法包括以下步骤:S1.构建新冠病毒结构蛋白拉曼光谱数据库;S2.构建新冠病毒核酸拉曼光谱数据库;S3.构建新冠病毒颗粒拉曼光谱数据库;S4.构建新冠病毒临床检测样本拉曼光谱数据库;将各新型冠状病毒拉曼光谱数据库存入新型冠状病毒拉曼光谱检测服务器构成新型冠状病毒拉曼光谱数据中心。本发明有效建立了一套完整的新型冠状病毒拉曼光谱数据库,为新冠病毒拉曼检测技术提供可靠的标准数据支撑,有效提高检测结果的准确性及置信度。 - link